Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy

Table 4 Relationship between several markers and chemotherapeutic response

	Non-response (n)	Total (n)	Multivariate HR^a (95% CI)^a,b	Multivariate HR (95% CI)^c
Total	112	250	–	–
Tumor grade
High-middle	91	193	Reference	Reference
Low	21	57	0.78 (0.54 ~ 1.13)	0.76 (0.53 ~ 1.11)
Tumor stage
LD^a	68	143	Reference	Reference
ED^a	44	107	0.86 (0.65 ~ 1.15)	0.84 (0.64 ~ 1.13)
EGFR^a
Negative	83	202	Reference	Reference
Positive	29	48	1.47 (1.11 ~ 1.95)	1.45 (1.09 ~ 1.93)
KRAS^a
Negative	101	234	Reference	Reference
Positive	11	16	1.59 (1.11 ~ 2.29)	1.57 (1.09 ~ 2.27)
Serum PD-L1^a
<7.0 ng/ml	45	122	Reference	Reference
≥ 7.0 ng/ml	67	128	1.42 (1.07 ~ 1.89)	1.40 (1.05 ~ 1.87)
Tissue PD-L1
Negative	17	50	Reference	Reference
Positive	28	48	1.75 (1.12 ~ 2.77)	1.76 (1.13 ~ 2.78)

^aLD: Limited disease; ED: Extensive disease; EGFR: Epidermal growth factor receptor; KRAS: Kirsten rat sarcoma viral oncogene; PD-L1: Programmed death ligand 1; HR: Hazard ratio; CI: Confidence interval
^bThe model was adjusted by age and gender
^cThe model was adjusted by age, gender, smoking history, performance status, tumor grade, tumor stage, tissue expressions of epidermal growth factor receptor and kirsten rat sarcoma viral oncogene

ISSN: 1465-993X